J Biomed Mater Res B Appl Biomater
Synechion, Inc., Dallas, TX 785248, USA.
Published: February 2004
The objective of the research was to determine the effect of the type, dose, and volume of anti-fibrinolytic agents (tranexamic acid, aprotinin) added to fibrin formulations, on adhesion development. Adhesions were induced in 228 male rats by creating apposing parietal and visceral peritoneal defects. Animals were randomized to receive no treatment or a fibrin formulation containing aprotinin or tranexamic acid. Seven days later the incidence of adhesions, and the force and energy required to detach them, were determined. Adhesions developed in 13/13 rats in the control and aprotinin groups. Treatment with fibrin (100 mg/ml tranexamic acid) resulted in adhesions in 4/14 rats (as strips, p < or = 0.0005), 4/10 rats (as spray, p < or = 0.0036), and 12/15 rats (by drip). The reduction of adhesions was dependent on the concentration of tranexamic acid with strip and spray application. Using commercial formulations, tranexamic-acid-containing fibrin (10/15, p = 0.042), but not aprotinin-containing fibrin (13/15), reduced the incidence of side-wall adhesions from 15/15 in controls. Fibrin containing either tranexamic or aprotinin reduced the incidence and severity of adhesions. This effect was greater when tranexamic acid was used and was dependent on the mode of administration, the volume, and to a degree, the concentration of tranexamic acid.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/jbm.b.20016 | DOI Listing |
Hypovolemic and hemorrhagic shock are life-threatening conditions that, if untreated, rapidly lead to multi-organ failure and death. These conditions result from significant intravascular fluid or blood loss, causing critical organ hypoperfusion. The underlying pathophysiology involves complex hemodynamic, inflammatory, and coagulation disturbances that may progress to irreversible organ dysfunction.
View Article and Find Full Text PDFAnn Hematol
March 2025
Pediatric hematology unit, Department of Pediatrics, Faculty of Medicine, Assiut University, Assiut, Egypt.
Background: Glanzmann's thrombasthenia (GT) is an inherited rare bleeding disorder characterized by a deficiency or functional defect in the platelet αIIbβ3 integrin. This impairs normal platelet aggregation and leads to prolonged and spontaneous mucocutaneous bleeds.
Objectives: To report disease characteristics of a GT cohort from five tertiary hospitals in Upper Egypt.
Eur Urol
March 2025
Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.
Anaesthesia
March 2025
NIHR Blood and Transplant Research Unit in Data Driven Transfusion Practice (BTRU), University of Oxford, UK.
Introduction: In UK hospitals, it is unclear how organisational structures are arranged to support effective implementation of peri-operative blood management practice strategies. The aim of this study was to conduct a national survey of organisations to describe local practices of peri-operative patient blood management and infrastructure availability in the UK.
Methods: A series of benchmarking standards was developed using recommendations informed by national standards, relevant literature and an expert panel.
Obes Surg
March 2025
Department of Surgery, Montefiore Medical Center, 3415 Bainbridge Ave, Bronx, NY, 10467, USA.
Recent research highlights TXA's potential in managing postoperative bleeding in bariatric surgery, prompting us to evaluate its effectiveness for treatment and prophylaxis. PubMed, Scopus, Cochrane Central, SciElo, and LILACS were searched for TXA studies in bariatric surgery, excluding those without control groups or with overlapping populations. Outcome analysis focused on postoperative bleeding, length of hospital stay (LOS), TXA side effects, mortality, transfusion needs, and thromboembolic complications.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.